Get the Stockscreener App
29.64
2.02%
-0.61
After Hours:
33.50
3.86
+13.02%
Kymera Therapeutics Inc stock is traded at $29.64, with a volume of 648.23K.
It is down -2.02% in the last 24 hours and down -12.02% over the past month.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
See More
Previous Close:
$30.25
Open:
$29.96
24h Volume:
648.23K
Relative Volume:
0.88
Market Cap:
$1.93B
Revenue:
$58.89M
Net Income/Loss:
$-240.88M
P/E Ratio:
-9.5613
EPS:
-3.1
Net Cash Flow:
$-239.96M
1W Performance:
+0.51%
1M Performance:
-12.02%
6M Performance:
-36.73%
1Y Performance:
-7.84%
1-Day Range:
$28.50
$29.96
1-Week Range:
$28.06
$30.28
52-Week Range:
$19.45
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Name
Kymera Therapeutics Inc
Sector
Industry
Phone
857-285-5314
Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
29.64 | 1.92B | 58.89M | -240.88M | -239.96M | -3.10 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Resumed | Stifel | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-26-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-22-24 | Initiated | Oppenheimer | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Jan-04-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-30-23 | Initiated | Truist | Buy |
| May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-06-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-08-22 | Initiated | Raymond James | Mkt Perform |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Aug-03-22 | Initiated | Goldman | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | JP Morgan | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Sep-30-21 | Initiated | B. Riley Securities | Neutral |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Sep-15-20 | Initiated | BofA Securities | Neutral |
| Sep-15-20 | Initiated | Cowen | Outperform |
| Sep-15-20 | Initiated | Guggenheim | Buy |
| Sep-15-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Kymera Therapeutics Inc Stock (KYMR) Latest News
Kymera Therapeutics (KYMR) Rises on Promising Phase 1 Data for K - GuruFocus
Kymera jumps 16% as it prepares to release phase 1 data on inflammatory diseases asset - Seeking Alpha
Kymera to report Phase 1 trial results of KT-621 on June 2 - Investing.com
Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025 | KYMR Stock News - GuruFocus
Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025 - The Manila Times
First-in-Human Data: Kymera's Novel Protein Degrader KT-621 Phase 1 Results Coming June 2 - Stock Titan
Kymera Therapeutics Lines Up 3 Key Investor Conferences: Jefferies, Goldman Sachs Lead June Calendar - Stock Titan
Millennium Management LLC Raises Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
BNP Paribas Financial Markets Acquires Shares of 9,838 Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Raises Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Research Analysts’ Recent Ratings Updates for Kymera Therapeutics (KYMR) - Defense World
Stifel Nicolaus Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - Defense World
Deutsche Bank AG Has $2.91 Million Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera Therapeutics (KYMR) Receives 'Buy' Rating from Stifel with $55 Price Target | KYMR Stock News - GuruFocus
Kymera Therapeutics (KYMR) Gains Buy Rating from Stifel with Promising Outlook | KYMR Stock News - GuruFocus
Kymera’s KT-621 shows promise in preclinical asthma study - Investing.com Australia
Kymera Therapeutics (KYMR) Showcases Promising Preclinical Data - GuruFocus
Kymera Therapeutics Presents New Preclinical Data for KT-621, a - GuruFocus
Kymera’s KT-621 shows promise in preclinical asthma study By Investing.com - Investing.com Canada
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference - The Manila Times
Kymera Therapeutics presents preclinical data for KT-621 - TipRanks
Breakthrough: New Oral Asthma Drug Shows Superior Results to Dupilumab in Latest Clinical Data - Stock Titan
Q2 EPS Estimate for Kymera Therapeutics Raised by Analyst - Defense World
Northern Trust Corp Has $17.61 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Transcript : Kymera Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com
Kymera at BofA Conference: Strategic FDA and Manufacturing Insights By Investing.com - Investing.com Nigeria
Kymera at BofA Conference: Strategic FDA and Manufacturing Insights - Investing.com
Kymera TherapeuticsIntriguing Degradation Thesis, But A Bit Powder Puff (NASDAQ:KYMR) - Seeking Alpha
Kymera Therapeutics (KYMR) Target Price Adjusted by UBS | KYMR S - GuruFocus
UBS Adjusts Price Target on Kymera Therapeutics to $70 From $72, Maintains Buy Rating - marketscreener.com
Kymera Therapeutics (KYMR) Target Price Revised by UBS | KYMR St - GuruFocus
Kymera Therapeutics (KYMR) Target Price Revised by UBS | KYMR Stock News - GuruFocus
Analysts Are Betting On Kymera Therapeutics, Inc. (NASDAQ:KYMR) With A Big Upgrade This Week - simplywall.st
When the Price of (KYMR) Talks, People Listen - news.stocktradersdaily.com
The Analyst Verdict: Kymera Therapeutics In The Eyes Of 4 Experts - Benzinga
Kymera Therapeutics (KYMR) Receives Reaffirmed 'Buy' Rating from - GuruFocus
Kymera Therapeutics (KYMR) Stock Rating Maintained, Price Target - GuruFocus
Kymera Therapeutics (KYMR) Faces Price Target Reduction Amid Str - GuruFocus
Truist maintains Kymera Therapeutics stock buy rating and $35 target By Investing.com - Investing.com UK
Kymera unveils new oral IRF5 degrader for immuno-inflammatory diseases - BioWorld MedTech
B. Riley Adjusts Kymera Therapeutics Price Target to $38 From $41, Maintains Neutral Rating - marketscreener.com
BofA Adjusts Price Target for Kymera Therapeutics (KYMR) | KYMR Stock News - GuruFocus
Kymera Therapeutics: Promising Pipeline and Strategic Decisions Justify Buy Rating - TipRanks
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript - Insider Monkey
Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Kymera advances oral drug for autoimmune diseases - Investing.com
Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up on Strong Earnings - Defense World
Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus
Kymera advances oral drug for autoimmune diseases By Investing.com - Investing.com India
Kymera Therapeutics Inc Stock (KYMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):